The interaction of immunocompetent cells and tumor endothelium represents an
essential precondition during immunologic recognition and defense against
malignant tumors. In the present study the degree of
leucocyte-endothelium-interaction was assessed in a newly developed model for in
vivo microscopy of the microcirculation of pancreatic cancer in the rat.
Methods: In 24 male Lewis rats (220-240g) tumor induction of a duct-like
pancreatic cancer (DSL6A, Am J Pathol 1993;143:292) was achieved
intraperitoneally by tumor fragment interposition (0.5x1mm) between 2
biologically inert transparent PMMA-plates. Tumor immunogeneity was proven by
mixed lymphocyte culture test (MLC). After 6 weeks an intravital microscopic
assessment of tumor microcirculation was performed in a temperature-controlled
immersion chamber. Five non-tumor-bearing animals served as controls. Parameters
were erythrocyte velocity, leucocyte-endothelium-interaction (Rhodamin 6G) and
vascular diameter. The calculation of the wall shear rates was performed
according to standard formulas. The observation was performed either in healthy
collecting venules (20-40 µm) or in tumor vessels of the same diameter.
Results: Tumor diameter in the tumor-bearing animals at the time of
observation was 3-4 mm. Erythrocyte velocity of normal pancreatic venules was
0.83 ±0.28 mm/sec (n=16) and in tumor vessels of equal diameter 1.06 ±0.62
mm/sec (n=52). Leucocyte-endothelium-interaction in healthy collecting
pancreatic venules showed 4.56 ±1.96 Rollers/100µm. In comparison
leucocyte-endothelium-interaction in pancreatic tumor vessels of equal diameter
was significantly reduced to 2.26 ±3.21 Rollers/100µm, p=0.009,
t-test). There was no correlation between leucocyte-endothelium-interaction and
wall shear rates in tumor vessels.
Conclusion: In experimental pancreatic cancer low-affinity
leucocyte-endothelium-interaction is substantially reduced despite similar wall
shear rates. This is the likely consequence of reduced adhesion molecule
expression and may represent a possible mechanism of host tumor immunotolerance.